Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Genotype-based treatments for movement disorders

Marcelo Kauffman • 17 Sep 2022
MDS 2022
Movement Disorders

Marcelo Kauffman, MD, PhD, Hospital JM Ramos Mejia, Buenos Aires, Argentina, discusses future treatment strategies for hyperkinetic movement disorders. Advances in genetics and the increased availability of genetic testing will enable the growth of treatment approaches based on the patient’s genotype, thus ushering the era of precision medicine for movement disorders. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marcelo Kauffman

Upcoming advances in genetic technologies
2:44
Upcoming advances in genetic technologies
Marcelo Kauffman • 17 Sep 2022
Challenges in the genomic evaluation of hyperkinetic movement disorders
2:04
Challenges in the genomic evaluation of hyperkinetic movement disorders
Marcelo Kauffman • 17 Sep 2022
The utility of genetic testing in the management of hyperkinetic movement disorders
3:47
The utility of genetic testing in the management of hyperkinetic movement disorders
Marcelo Kauffman • 17 Sep 2022

Related Videos

Emerging therapies for neurologic Wilson's disease
2:42
Emerging therapies for neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Findings from the Phase III FoCus trial: tiomolibdate choline for neurologic Wilson's disease
3:18
Findings from the Phase III FoCus trial: tiomolibdate choline for neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Current treatment and unmet needs in neurologic Wilson's disease
3:15
Current treatment and unmet needs in neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Guidance for clinicians on the real-world use of foslevodopa/foscarbidopa for PD
7:39
Guidance for clinicians on the real-world use of foslevodopa/foscarbidopa for PD
K. Ray Chaudhuri • 30 Jun 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals